camptothecin has been researched along with glucagon-like peptide 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Bateman, EH; Bowen, JM; Keefe, DM; Mayo, BJ; Stringer, AM | 1 |
1 review(s) available for camptothecin and glucagon-like peptide 2
| Article | Year |
|---|---|
Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.
Topics: Anti-Bacterial Agents; Antidiarrheals; Apoptosis; Camptothecin; Cholinergic Antagonists; Gastrointestinal Microbiome; Glucagon-Like Peptide 2; Humans; Irinotecan; Mucositis | 2017 |
1 other study(ies) available for camptothecin and glucagon-like peptide 2
| Article | Year |
|---|---|
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |